Helix Acquisition Corp. II closes $184M IPO, including full over-allotment

BridgeBio Oncology Therapeutics, Inc.

Closed IPO of 18.4M Class A shares at $10.00 each; gross proceeds $184M.
Underwriter exercised over-allotment option in full for additional 2.4M shares.
Sponsor purchased 509,000 private placement shares at $10.00 for $5.09M.
Total $184M placed in trust; must complete business combination within 24 months.
Appointed Mark C. McKenna and John Schmid as independent directors; charter amended.

item 1.01 item 3.02 item 5.02 item 5.03 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John Schmid

Director

BBOT · BridgeBio Oncology Therapeutics, Inc.

Effective: 2024-02-08
Filed: February 14, 2024, 6:59 PM ET

Mr. Mark C. McKenna and Mr. John Schmid (the “ Directors ”) were appointed to the board of directors of the Company

Appointed

Mark C. McKenna

Director

BBOT · BridgeBio Oncology Therapeutics, Inc.

Effective: 2024-02-08
Filed: February 14, 2024, 6:59 PM ET

Mr. Mark C. McKenna and Mr. John Schmid (the “ Directors ”) were appointed to the board of directors of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John Schmid was appointed as Director at BridgeBio Oncology Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

Mr. Mark C. McKenna and Mr. John Schmid (the “ Directors ”) were appointed to the board of directors of the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark C. McKenna was appointed as Director at BridgeBio Oncology Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

Mr. Mark C. McKenna and Mr. John Schmid (the “ Directors ”) were appointed to the board of directors of the Company

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

BridgeBio Oncology Therapeutics, Inc.: Amended and restated memorandum and articles of association filed and became effective in connection with IPO (effective 2024-02-08).

Change: charter amendment
Effective: 2024-02-08

Exact text from the filing

On February 8, 2024, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “ Amended Charter ”) with the Cayman Islands General Registry, effective the same day.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BridgeBio Oncology Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC (effective 2024-02-08).

Action: entry
Agreement: underwriting
Counterparty: Leerink Partners LLC
Effective: 2024-02-08

Exact text from the filing

n January 18, 2024 (as amended, the “ Registration Statement ”): ● An Underwriting Agreement, dated February 8, 2024, between the Company and Leerink Partners LLC, a copy of which is attached as Exhibit 1.1 hereto and incorporated herein by reference.

View on SEC.gov

188 governance changes filed in the last 30 days. Browse all governance changes →

BridgeBio Oncology Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-013637

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.